drugset
drugset / Trial / NCT05323136

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

NCT05323136 ↗

Phase 1 Terminated 2 enrolled Shaanxi Micot Pharmaceutical Technology Co., Ltd.
RandomizedSequentialOpen-labelTreatment

Summary

The study is a multicenter, Phase 1, open-label, sequential, adaptive, single dose, PK/PD study in subjects with moderate and severe RI and healthy volunteers (HV).

Timeline

Start
2022-04-15
Primary completion
2022-06-29
Completion
2022-06-29

Outcome

Outcome not reported

Stopped (Business): “Strategic decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject MT1002 Peptide 1.8 mg/kg Intravenous

Indications

acute coronary syndrome